The Food and Drug Administration announced a national recall of the prescription arthritis medication Tyenne, citing the presence of glass particles in certain vials. Tyenne, a biologic used to treat adults with moderate to severe rheumatoid arthritis who have not responded to other disease‑modifying antirheumatic drugs, is marketed under the generic name tocilizumab‑aazg.
What prompted the recall
During a routine internal review, the manufacturer identified glass fragments in a specific lot of 400 mg/20 mL vials. The FDA’s enforcement report lists the affected lot as 16UI07, with an expiration date of August 2028. The agency warns that injecting a contaminated vial can cause local irritation, pain, swelling, or vein inflammation at the infusion site.
Potential health risks
Beyond local reactions, the glass particles could obstruct veins, potentially cutting off blood flow to vital organs. In severe cases, this blockage may lead to a life‑threatening pulmonary embolism, permanent organ damage, or death. To date, the FDA has not reported any injuries linked to the recall, but it urges immediate discontinuation of use for the affected lot.
How to determine if you have the recalled product
Consumers and health‑care providers should check the following details on the vial packaging:
- Product: Tyenne (tocilizumab‑aazg) Injection
- Strength: 400 mg / 20 mL (20 mg/mL)
- NDC number: 65219‑594‑20
- Product code: 590120
- Lot number: 16UI07
- Expiration date: 08/2028
Photographs of the labeling and packaging are available in the FDA’s enforcement report for reference.
What to do with the medication
Anyone who possesses a vial matching the above specifications should stop using it immediately and return it to the manufacturer. The recall phone line is 1‑866‑716‑2459 for questions about the return process.
If a patient has already received an injection from the recalled lot and experiences any unusual symptoms—such as persistent pain, swelling, shortness of breath, or signs of a blood clot—they should contact their health‑care provider right away. Adverse events can also be reported directly to the manufacturer via 1‑800‑551‑7176 or by emailing productcomplaint.USA@fresenius‑kabi.com or adverse.events.USA@fresenius‑kabi.com.
Broader context
Tyenne is part of a class of biologic therapies that have transformed the management of rheumatoid arthritis, offering relief for patients who have exhausted traditional DMARDs. While recalls of injectable biologics are rare, this incident underscores the importance of rigorous quality‑control measures throughout the manufacturing process.
Patients should continue to work closely with their rheumatologists to explore alternative treatment options if needed, and to stay informed about any further updates from the FDA or the drug’s manufacturer.
Original reporting: 40/29 / KHBS (NW Arkansas) — read the source article.
